These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 38609037)

  • 1. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2.
    Ganguly S; Rosenthal SB; Ishizuka K; Troutman TD; Rohm TV; Khader N; Aleman-Muench G; Sano Y; Archilei S; Soroosh P; Olefsky JM; Feldstein AE; Kisseleva T; Loomba R; Glass CK; Brenner DA; Dhar D
    Proc Natl Acad Sci U S A; 2024 Aug; 121(35):e2405746121. PubMed ID: 39172787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.
    Chen X; Peng R; Peng D; Liu D; Li R
    J Transl Med; 2024 Jul; 22(1):701. PubMed ID: 39075482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.
    Hvid H; Hjuler ST; Bedossa P; Tiniakos DG; Kamzolas I; Harder LM; Xue Y; Perfield JW; Kirk RK; Latta M; Mikkelsen LF; Pedersen HD;
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G571-G585. PubMed ID: 39041677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-salt diet downregulates TREM2 expression and blunts efferocytosis of macrophages after acute ischemic stroke.
    Hu M; Lin Y; Men X; Wang S; Sun X; Zhu Q; Lu D; Liu S; Zhang B; Cai W; Lu Z
    J Neuroinflammation; 2021 Apr; 18(1):90. PubMed ID: 33845849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy.
    Wang Q; Bu Q; Xu Z; Liang Y; Zhou J; Pan Y; Zhou H; Lu L
    Clin Mol Hepatol; 2024 Jul; 30(3):515-538. PubMed ID: 38726504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triggering Receptors Expressed on Myeloid Cells 2 Promotes Corneal Resistance Against
    Qu W; Wang Y; Wu Y; Liu Y; Chen K; Liu X; Zou Z; Huang X; Wu M
    Front Immunol; 2018; 9():1121. PubMed ID: 29887864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.
    Abdelnabi MN; Hassan GS; Shoukry NH
    Front Immunol; 2024; 15():1437046. PubMed ID: 39156888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis.
    Shan S; Chao S; Liu Z; Wang S; Liu Z; Zhang C; Cheng D; Su Z; Song F
    Free Radic Biol Med; 2024 Aug; 220():154-165. PubMed ID: 38710340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP activation in liver macrophages via depletion of MST1/MST2 enhances liver inflammation and fibrosis in MASLD.
    Zhang J; Chen W; Song K; Song K; Kolls J; Wu T
    FASEB J; 2024 Sep; 38(17):e70026. PubMed ID: 39215627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic danger signaling triggers TREM2
    Zhou L; Qiu X; Meng Z; Liu T; Chen Z; Zhang P; Kuang H; Pan T; Lu Y; Qi L; Olson DP; Xu XZS; Chen YE; Li S; Lin JD
    Sci Transl Med; 2024 Mar; 16(738):eadk1866. PubMed ID: 38478630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.